

Jennifer S Gewandter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1407851/publications.pdf>

Version: 2024-02-01

73
papers

2,060
citations

218677

26
h-index

254184

43
g-index

73
all docs

73
docs citations

73
times ranked

2940
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1019-1028.	2.2	208
2	The ACTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. <i>Journal of Pain</i> , 2014, 15, 241-249.	1.4	159
3	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. <i>Pain</i> , 2016, 157, 1836-1850.	4.2	152
4	Research design considerations for chronic pain prevention clinical trials. <i>Pain</i> , 2015, 156, 1184-1197.	4.2	115
5	Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2014, 155, 1683-1695.	4.2	99
6	A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. <i>Supportive Care in Cancer</i> , 2014, 22, 1807-1814.	2.2	92
7	Trial designs for chemotherapy-induced peripheral neuropathy prevention. <i>Neurology</i> , 2018, 91, 403-413.	1.1	63
8	Measures of outcome for stimulant trials: ACTION recommendations and research agenda. <i>Drug and Alcohol Dependence</i> , 2016, 158, 1-7.	3.2	49
9	Idiopathic distal sensory polyneuropathy. <i>Neurology</i> , 2020, 95, 1005-1014.	1.1	49
10	Pain intensity rating training. <i>Pain</i> , 2016, 157, 1056-1064.	4.2	48
11	Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 1543-1552.	2.2	46
12	Data Interpretation in Analgesic Clinical Trials With Statistically Nonsignificant Primary Analyses: An ACTION Systematic Review. <i>Journal of Pain</i> , 2015, 16, 3-10.	1.4	42
13	The ACTIONâ€‘APSâ€‘AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions. <i>Pain Medicine</i> , 2017, 18, 947-958.	1.9	42
14	Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. <i>Neurology</i> , 2015, 84, 265-272.	1.1	39
15	The ACTIONâ€‘APSâ€‘AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions. <i>Journal of Pain</i> , 2017, 18, 479-489.	1.4	38
16	Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations. <i>Pain</i> , 2021, 162, 1935-1956.	4.2	38
17	Chemotherapy-induced peripheral neuropathy clinical trials. <i>Neurology</i> , 2017, 89, 859-869.	1.1	37
18	Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations. <i>Journal of Pain</i> , 2020, 21, 931-942.	1.4	37

#	ARTICLE	IF	CITATIONS
19	Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTION individual patient data analysis. <i>Pain</i> , 2018, 159, 2245-2254.	4.2	36
20	Composite outcomes for pain clinical trials: considerations for design and interpretation. <i>Pain</i> , 2021, 162, 1899-1905.	4.2	35
21	Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTION systematic review and recommendations. <i>Pain</i> , 2014, 155, 1871-1877.	4.2	34
22	Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S13-S25.	3.1	34
23	Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. <i>Supportive Care in Cancer</i> , 2020, 28, 2553-2562.	2.2	33
24	Reporting of Sample Size Calculations in Analgesic Clinical Trials: ACTION Systematic Review. <i>Journal of Pain</i> , 2015, 16, 199-206.e7.	1.4	32
25	Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. <i>Supportive Care in Cancer</i> , 2019, 27, 1765-1774.	2.2	29
26	Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations. <i>BMJ Open</i> , 2017, 7, e017288.	1.9	26
27	Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. <i>Pain Reports</i> , 2019, 4, e621.	2.7	26
28	Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTION systematic review and recommendations. <i>Pain</i> , 2014, 155, 461-466.	4.2	25
29	Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 204-210.	4.7	24
30	Associations between a patient-reported outcome (PRO) measure of sarcopenia and falls, functional status, and physical performance in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 433-441.	1.0	23
31	Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 3303-3311.	2.2	23
32	Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review. <i>Muscle and Nerve</i> , 2021, 63, 170-177.	2.2	22
33	Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?. <i>Pain</i> , 2017, 158, 30-33.	4.2	21
34	Estimands and missing data in clinical trials of chronic pain treatments: advances in design and analysis. <i>Pain</i> , 2020, 161, 2308-2320.	4.2	21
35	Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. <i>Pain</i> , 2021, 162, 2669-2681.	4.2	20
36	Clinician-rated measures for distal symmetrical axonal polyneuropathy. <i>Neurology</i> , 2019, 93, 346-360.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. <i>Pain</i> , 2016, 157, 2544-2551.	4.2	16
38	Navigating trials of personalized pain treatments: we're going to need a bigger boat. <i>Pain</i> , 2019, 160, 1235-1239.	4.2	15
39	Evaluation of outcome measures for neurogenic claudication. <i>Neurology</i> , 2015, 85, 1250-1256.	1.1	14
40	Deficiencies in reporting of statistical methodology in recent randomized trials of nonpharmacologic pain treatments: ACTION systematic review. <i>Journal of Clinical Epidemiology</i> , 2016, 72, 56-65.	5.0	13
41	Reporting of intention-to-treat analyses in recent analgesic clinical trials: ACTION systematic review and recommendations. <i>Pain</i> , 2014, 155, 2714-2719.	4.2	12
42	Comparison of a Pain Tolerability Question With the Numeric Rating Scale for Assessment of Self-reported Chronic Pain. <i>JAMA Network Open</i> , 2020, 3, e203155.	5.9	12
43	Brain Imaging Biomarkers for Chronic Pain. <i>Frontiers in Neurology</i> , 2021, 12, 734821.	2.4	12
44	Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTION systematic review. <i>Journal of Clinical Epidemiology</i> , 2017, 83, 101-107.	5.0	9
45	Systematic Review of Research Methods and Reporting Quality of Randomized Clinical Trials of Spinal Cord Stimulation for Pain. <i>Journal of Pain</i> , 2021, 22, 127-142.	1.4	9
46	Peripheral edema: A common and persistent health problem for older Americans. <i>PLoS ONE</i> , 2021, 16, e0260742.	2.5	9
47	Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTION Adaptive Choice-Based Conjoint Study. <i>Journal of Pain</i> , 2016, 17, 1198-1206.	1.4	8
48	Why are there no drugs indicated for sciatica, the most common chronic neuropathic syndrome of all?. <i>Drug Discovery Today</i> , 2018, 23, 1904-1909.	6.4	8
49	Design and Reporting Characteristics of Clinical Trials of Select Chronic and Recurrent Pediatric Pain Conditions: An Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks Systematic Review. <i>Journal of Pain</i> , 2019, 20, 394-404.	1.4	8
50	DNA double-strand breaks activate ATM independent of mitochondrial dysfunction in A549 cells. <i>Free Radical Biology and Medicine</i> , 2014, 75, 30-39.	2.9	7
51	Reporting of adverse events and statistical details of efficacy estimates in randomized clinical trials of pain in temporomandibular disorders. <i>Journal of the American Dental Association</i> , 2015, 146, 246-254.e6.	1.5	7
52	Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: An ACTION Systematic Review. <i>Journal of Pain</i> , 2018, 19, 717-726.	1.4	7
53	Extended-release gabapentin for failed back surgery syndrome: results from a randomized double-blind cross-over study. <i>Pain</i> , 2019, 160, 1029-1036.	4.2	7
54	EXCAP exercise to improve fatigue, cardiopulmonary function, and strength: A phase II RCT among older prostate cancer patients receiving radiation and androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9010-9010.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Partnering with patients in clinical trials of pain treatments: a narrative review. <i>Pain</i> , 2022, 163, 1862-1873.	4.2	6
56	Interpretation of Urine Drug Testing Results in Patients Using Transdermal Buprenorphine Preparations for the Treatment of Chronic Noncancer Pain: Table 1. <i>Pain Medicine</i> , 2015, 16, 1132-1136.	1.9	5
57	Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. <i>Pain Reports</i> , 2021, 6, e895.	2.7	5
58	Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials. <i>Pain</i> , 2020, 161, 195-201.	4.2	4
59	Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. <i>Pain</i> , 2022, 163, 1006-1018.	4.2	4
60	Evaluating predictors of pain reduction after genicular nerve radiofrequency ablation for chronic knee pain. <i>Pain Management</i> , 2021, 11, 669-677.	1.5	4
61	Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2019, 27, 7-8.	2.2	3
62	Predicting Treatment Response with Sensory Phenotyping in Post-Traumatic Neuropathic Pain. <i>Pain Medicine</i> , 2022, 23, 1726-1732.	1.9	3
63	YOCAS yoga for musculoskeletal symptoms in breast cancer patients receiving aromatase inhibitors: A URCC CCOP randomized, controlled clinical trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9028-9028.	1.6	2
64	Pain, sleep disturbance, and fatigue symptom cluster in patients suffering from chronic chemotherapy-induced neuropathic pain (CINP).. <i>Journal of Clinical Oncology</i> , 2012, 30, 9113-9113.	1.6	2
65	Design and reporting characteristics of clinical trials investigating sedation practices in the paediatric intensive care unit: a scoping review by SCEPTER (Sedation Consortium on Endpoints and) Tj ETQq1 1 0.784314 rgt /Over		
66	The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11590-11590.	1.6	2
67	Reply. <i>Pain</i> , 2017, 158, 182-183.	4.2	1
68	Identifying chemotherapy-induced peripheral neuropathy (CIPN) and its treatment using claims data: A URCC NCORP and NIH Collaboratory study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18707-e18707.	1.6	1
69	Evaluation of the psychometric properties of patient-reported and clinician-reported outcome measures of chemotherapy-induced peripheral neuropathy: a COSMIN systematic review protocol. <i>BMJ Open</i> , 2022, 12, e057950.	1.9	1
70	When should non-significant results influence clinical decisions?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 548-549.	2.3	0
71	Falls, physical performance deficits, and functional losses in cancer survivors with chemotherapy-induced neuropathy (CIPN): A University of Rochester CCOP study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9014-9014.	1.6	0
72	Physical symptoms and psychological distress in head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16056-e16056.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Pretreatment physical activity to predict short- and long-term chemotherapy-induced peripheral neuropathy (CIPN) in a nationwide longitudinal study of paclitaxel for breast cancer.. Journal of Clinical Oncology, 2018, 36, 10018-10018.	1.6	0